Revolution Medicines reports daraxonrasib trial meets survival endpoints

April 13, 2026 8:02 AM

Revolution Medicines announced that its Phase 3 RASolute 302 trial of daraxonrasib met primary and secondary endpoints in patients with ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found